scholarly journals COMPARISON OF INSULIN GLARGINE WITH HUMAN PREMIX INSULIN IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL HYPOGLYCEMIC DRUGS IN A 24-WEEK RANDOMIZED STUDY AMONG INDIAN POPULATION

2013 ◽  
Vol 2 (2) ◽  
pp. 166-174
Author(s):  
Abhishek Singhai ◽  
Subodh Banzal ◽  
Dolly Joseph ◽  
Rajesh Kumar Jha ◽  
Pragya Jain
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Indian Population ◽  
Randomized Study ◽  
Premix Insulin ◽  
Oral Hypoglycemic Drugs

scholarly journals Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study

2018 ◽  
Vol 20 (7) ◽  
pp. 1602-1614 ◽  
Author(s):  
Cristian Guja ◽  
Juan P. Frías ◽  
Aniko Somogyi ◽  
Serge Jabbour ◽  
Hui Wang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Randomized Study ◽  
Exenatide Qw

scholarly journals Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Menghui Luo ◽  
Xiaocen Kong ◽  
Huiying Wang ◽  
Xiaofang Zhai ◽  
Tingting Cai ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Insulin Glargine ◽  
Beta Cell Function ◽  
Cell Function ◽  
Pancreatic Beta Cell ◽  
Glycemic Variability ◽  
Oral Hypoglycemic Drugs ◽  
Pancreatic Beta Cell Function

Aim. To evaluate the effect of an inhibitor of sodium-glucose cotransporter 2 (SGLT-2 inhibitor, dapagliflozin) on glycemic variability in type 2 diabetes mellitus (T2D) under insulin glargine combined with oral hypoglycemic drugs, using a continuous glucose monitoring system (CGMS). Methods. This prospective, self-controlled, single-center clinical trial recruited 36 patients with T2D under combined insulin glargine and oral hypoglycemic drugs. General clinical data were collected. Fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), and C-peptide levels were assessed before and four weeks of dapagliflozin (10 mg per day) treatment. Blood glucose was monitored for 72 hours before and after treatment using CGMS. Results. After treatment with dapagliflozin, FBG decreased from 6.74 ± 1.78 to 5.95 ± 1.13  mmol/L ( p < 0.05 ); PBG decreased from 13.04 ± 2.99 to 10.92 ± 3.26  mmol/L ( p < 0.05 ); HbA1c decreased from 7.37 ± 0.96 % to 6.94 ± 0.80 % . The proportion of patients with HbA 1 c < 7 % increased from 27.8% to 58.3%, and the proportion of patients with HbA 1 c < 7 % and without level 2 hypoglycemia increased from 27.8% to 55.6% ( p < 0.05 ). CGMS data showed reduction of the 24 h MBG, MAGE, time-above-range (TAR, >10 mmol/L), high blood glucose index (HBGI), glucose management indicator (GMI), and incremental area under the curve of the glucose level more than 10 mmol/L ( AUC > 10 ) and an increase of time-in-range (TIR, 3.9-10 mmol/L) with treatment. Homeostasis model assessment for pancreatic beta-cell function (HOMA-beta) increased significantly with treatment ( p < 0.05 ), and fewer insulin doses were required after the treatment, without increasing in hypoglycemia and urinary tract infection. Further, a stratified analysis showed that patients with higher pretreatment HbA1c and waist-to-hip ratio (WHR) had greater improvement in glycemic control. Conclusion. Dapagliflozin may reduce blood glucose levels, ameliorate glycemic variability, and improve pancreatic beta-cell function in patients with T2D under insulin glargine combined with other oral hypoglycemic drugs, especially in those with poor glucose control and abdominal obesity.

Sign in / Sign up

Export Citation Format

Share Document